Mindray Makes Subtle Move Into Orthopedics
Executive Summary
China’s international medical device leader Mindray Medical International Ltd. entered the rough-and-tumble Chinese orthopedics industry. The company accquired a controlling stake in Wuhan Dragonbio Surgical Implant Co. Ltd., a small China-based supplier of trauma, large joint and spine products. The purchase pits Mindray – which sells large durable medical equipment across the globe ( against larger China-based companies like China Kanghui Holdings, Shandong Weigao Group Medical Polymer Co. Ltd. and Trauson Medical Instrument Co. Ltd., as well as multinationals. Dragonbio is a bit player in the Chinese orthopedics market. But Mindray ( which is projected to report $1 billion in sales this year – likely won’t be content with that place on the pecking order.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.